Tumor necrosis factor inhibitors and uveitis: Comment on the article by Lim et al.

Arthritis and Rheumatism

Volumn 58, Issue 5, 2008, Pages 1554-1555

  Sfikakis, Petros P ^a   Markomichelakis, Nikos ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b KAT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; DISEASE REGISTRY; DRUG EFFECT; DRUG INDICATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LETTER; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; UVEITIS;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 43949137247     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23442     Document Type: Letter

References (5)

1. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-52.
2. Theodossiadis PG, Markomichelakis N, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation [review]. Retina 2007;27:399-413.
3. Paivonsalo-Hietanen T, Tuominen J, Vaahtoranta-Lehtonen H, Saari KM. Incidence and prevalence of different uveitis entities in Finland. Act Ophthalmol Scand 1997;75:76-81.
4. Fonollosa A, Segura A, Giralt J, Garcia-Arumi J. Tuberculous uveitis after treatment with etanercept. Graefes Arch Clin Exp Ophthalmol 2007;245:1397-9.
5. Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, et al. Anti-TNF therapy in the management of Behcet's disease: review and basis for recommendations [review]. Rheumatology (Oxford) 2007;46:736-41.